In our article on abuse-deterrent opioids (Med Lett Drugs Ther 2017; 59:95) , the information on Targiniq ER in Table 1 is incorrect. The drug, which is not available in the US, is a combination of oxycodone…
Med Lett Drugs Ther. 2018 Jul 16; 60(1551):122
In our article on abuse-deterrent opioids (Med Lett Drugs Ther 2017; 59:95) , the information on Targiniq ER in Table 1 is incorrect. The drug, which is not available in the US, is a combination of oxycodone ER and naloxone, not naltrexone, and naloxone is dispersed throughout the tablet, not sequestered. Targiniq ER will be deleted from the table in the article as it appears on our website.
The FDA has approved Arymo ER (Egalet), a new extended-release, abuse-deterrent tablet formulation of morphine sulfate, for management of pain severe enough to require daily, around-the-clock, long-term opioid…
Med Lett Drugs Ther. 2017 Apr 24; 59(1519):68-9
The FDA has approved Arymo ER (Egalet), a new extended-release, abuse-deterrent tablet formulation of morphine sulfate, for management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Arymo ER can only be marketed to deter abuse by injection because another single-entity, extended-release morphine product, MorphaBond , which has not been marketed to date, has marketing exclusivity for deterrence of abuse by the intranasal route through October 2018.
The FDA has approved Xtampza ER (Collegium), a new extended-release, abuse-deterrent capsule formulation of oxycodone, for management of pain severe enough to require daily, around-the-clock, long-term opioid…
Med Lett Drugs Ther. 2016 Jun 20; 58(1497):77-8
The FDA has approved Xtampza ER (Collegium), a new extended-release, abuse-deterrent capsule formulation of oxycodone, for management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.
Development of abuse-deterrent opioid products, including reformulation of existing products, has become a priority for drug manufacturers and public health advocates. Three available opioid formulations,…
Med Lett Drugs Ther. 2015 Aug 31; 57(1476):119-21
Development of abuse-deterrent opioid products, including reformulation of existing products, has become a priority for drug manufacturers and public health advocates. Three available opioid formulations, OxyContin (Purdue), Embeda (Pfizer), and Hysingla ER (Purdue), now include claims of abuse deterrence in their package inserts.